PolarityTE — Investor Presentation (March 2017)
54 slides from PolarityTE's investor presentation, Mar 13, 2017
Slide 1: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of projections, as to their attainability or the accuracy and completeness o
Slide 2: Opportunity, Strategy, Pipeline, Partnering, Team
OPPORTUNITY Early growth stage regenerative medicine company with a platform technology able to create y functional tissue, beginning with regenerated skin that grows all layers, glands, and hair STRATEGY 0 « Rapid clinical and market deployment of first launch product SkinTE™ to capture massive wou
Slide 3: Global Regenerative Medicine and Wound Care Markets
Global Regenerative Medicine and Wound Care Markets ® Current markets remain untapped with redundant Growth in Worldwide Prevalence of products and no autologous (patient’s own tissue/cells) Memes no aoeD tissue engineering ae {| © Complicated skin cancer 20000 Melanoma ® The global market for tissu
Slide 4: The PolarityTE Platform Technology
The PolarityTE™ Platform Technology Discovered through careful observation of tissue regeneration in real-time, the PolarityTE™ Platform Technology has proved its regenerative capacity in SKIN, bone, muscle, fat, cartilage, nerve, Muscle Lo
Slide 5: Development Pipeline
Development Pipeline June 2017 > December 2017 >
Slide 6: The PolarityTE Launch Product
The PolarityTE Launch Prod Using our platform technology, we are able to regenerate full-thickness, fully functional skin. This simple process allows the patient’s own skin to be fully expanded from a small biopsy. The expanded skin regenerates ALL LAYERS (EPIDERMIS & DERMIS), HAIR and APPENDAGES, w
Slide 7: Physiology of Skin and Wound Healing
Physiology of Skin and Wound Healin Inflammatory phase THREE PHASES OF WOUND HEALING Inflammatory Phase (Days) Immediately following injury and wound creation Vessel contraction, clot formation, control of bleeding Inflammatory mediators and inflammatory cells accumulate and clean wound Proliferativ
Slide 8: Current Therapies
Current Therapies INTEGRA Integra Bilayer Matrix ~~ a Provides a potential solution for difficult wounds unable to accept a skin graft (exposed bone or tendon) ® Only product routinely used by reconstructive surgeons 2 $300M in revenue, overall Market Cap $3.28B including other surgical devices Sh A
Slide 9: Current Therapies Lack Building Blocks for Regeneration
for Regeneration Building Bloc Skin Substitute Products Considered in This Report: Therapies Lack t TaN POTEET PINT Matrix MatriStem 1 AlloDerm oflex® Technology Assessment Primat ative Tissue Matrix Primat hronic Wounds Jaloskin Suprathel® Talymed® DressSkin E-Z Derm “orm Dermal Te Animals Cells, A
Slide 10: Current Therapies: Limitations
Current Therapies: Limitations Oh CAlloDerm ermagraft. Human fibroblast-derived dermal substitute AlloSourceé Ul ’ <> —_ Apligraf add life to healing
Slide 11: Current Therapies: Limitations of Autologous Options
Current Therapies: Limitations of Autologous Options me " a Epidermis How EPICEL is Made o Old i —~—— Split thickness Dermis Full thickness G Animal Cells
Slide 12: Can Any Current Therapy Regenerate All Layers of Skin?
Can ANY Current Therapy sige to ONE of UNESEr
Slide 13: The Gold Standard: Split-Thickness Skin Grafts
The Gold Standard: Split-Thickness Skin Grafts HOW PROBLEMS _ 1. Donor Site Morbidity & Pain Skin ismeshed 2. Stem Cell is Left Behind with Loss of Polarity 7 large wound 3. Contracture and Scarring 4. Non-functional Skin Graft taken from 4 patient's healthy skin > The Follicular Bulge Left Behind H
Slide 14: The REAL Problem: All Tissues Require Polarity
The REAL Problem All Tissues Require Polarity
Slide 15: Without Polarity Function is Lost
Without Polarity Function is Lost polarity, the tendency of living organisms or parts to evelop with distinct anterior and posterior (or uppermost ad lowermost) ends, or to grow or orient in a particular irection.
Slide 16: Polarity Drives Hierarchical Tissue Formation
Polarity Drives Hierarchical Tissue Formation
Slide 17: Polarity
Polarity Developmen Skin Cells Neuron Pigment of Epidermis of Brain Cell Sperm Egg a Ox = — 7 Ry fave ~—S @) Ai ww dbf : Q Ectoderm Germ (External Layer) Cells Cardiac Muscle Mesoderm (Middle Layer) mr Skeletal Tubule Red Blood Smooth Muscle = Cellofthe Cells Cells Kidney Muscle {in Gut) Endoderm (I
Slide 18: 3 Primary Germ Layers Make All Tissues
A. Ectoderm 1. Epidermis 2. Brain 3. Glands 4. Keratinous Cell 5. Neuron 6. Spinal Cord 7. Neuron 8. Milk-Secreting Glands 9. Light-Sensing Cells 10. Adrenal Medulla 11. Pigment Cell B. Mesoderm 12. Cartilage Connective Tissue 13. Gonads 14. Cartilage Tissue Cell 15. Striated Muscle Tissue 16. Adren
Slide 19: Skin is Derived from Multiple Germ Layers
Skin is Derived from Multiple Germ Ectoderm Origin Mesoderm Origin The Interface
Slide 20: Slide 20
Slide 21: Slide 21
Slide 22: Experts Agree with PolarityTE Approach
Experts Agree with PolarityTE Approac “\Ne are enthusiastic to see the future of this exciting work.” — Michael Longaker on Lough et al. technology EXPERIMENTA DISCUSSION . . a Discussior Transplantation of the LGR6* Epithelial Stem) and LGR6' Stem h the GutDeri Celene Nd for Ret EGR: Epithet Sofeis
Slide 23: The PolarityTE Launch Product
The PolarityTE Launch Prod Using our platform technology, we are able to regenerate full-thickness, fully functional skin. This simple process allows the patient’s own skin to be fully expanded from a small biopsy. The expanded skin regenerates ALL LAYERS (EPIDERMIS & DERMIS), HAIR and APPENDAGES, w
Slide 24: Stem Cells with a Variety of Vectors for Delivery
stem with a Variety of Vectors for Delive Final Sort Gate. | wt ” ra £2 D7 EXPERIMENTAL LGR6+ CD34+ Fel GFP | 3= cO3+ ri 7 Transplantation of the LGR6* Epithelial Stem ro et Cell Fluorescence 7 PE-Cy7 Cell into Full-Thickness Cutaneous Wounds = LGR6 £2 Results in Enhanced Healing, Nascent Hair ei)"
Slide 25: Proliferation and Scaffold Imprinting
Proliferation and Scaffold Imprinting 4 i WAV,
Slide 26: Rapid/Complete Proliferation 48-72 Hours Ex-Vivo
Rapid/Complete Proliferation 48-72 Hours Ex-Vivo
Slide 27: Fully Functional Regenerated Skin with Hair Growth in a Nude Mouse
Fully Functional Regenerated Skin with Hair Growth in a Nude Mouse Control LGR6*¢F Day 15 Implant Pocket iy, | LGRE*SFP a) ee A i > ie ee ° as _| a. - Ty ‘4 »* Day 6 © & | ofl 65 Ne: 3 ay ay] Control
Slide 28: Transplantation of a LGR6+ Epithelial Stem Cell-Enriched Scaffold
Transplantation of a LGR6* Epithelial Stem Cell-Enriched Scaffold for Repair of Full-Thickness Soft Tissue Defects: fitro Development of Polarized Hair Bearing Skin. Lough et al. ‘Activated Cell Sorting 1GR6+/C073+/cD34+ Q2. | Microscopy Bioluminescence Merge Zoom Control 16*GFP Live Cell Ex-Vi Matr
Slide 29: Angiogenesis
Angiogenesis Relative Fold Expression (A0Ct) Wound Healing EGF/ PDGF Blood Vessel Forming Genes and Protei RELATIVE PROTEIN DENSITOMETRY eo 8 8 BEES Hy 8 TE ee ee wat 2 mee For acibie eer ae ea es — es singe 2 8 rorensell oie ASSES SLESOEIUE TEE SSS EEE oo SE ahead Se reacrautin fl goo g 8 3 500 g F
Slide 30: SEM Validation of Viability and Phenotype
SEM Validation of Viability and Phenotype Integra DermaMatrix
Slide 31: OO LSPAAD ES MUD Sta DOOODD: B tad
e ~ OO LSPAAD ES MUD Sta DOOODD: B tad ) = = oe 3 ae tings winos >»
Slide 32: Maintain Viable Bio-reactive Tissue
Maintain Viable Bio-reactive Tissue |
Slide 33: Development of Functionally Polarized Skin
Development of Functionally Polarized Skin LGR6 Layered Epithelium Ski nlc Sub-epithelial Mesenchymal Support and Vasculogenesis
Slide 34: Augment Regenerative Healing
Augment Regenerative Healing ») \I KInT | L Gross Matrix Gross Matrix Healing LGR+ —_ Healing LGR+ The enhanced healing can be seen with the naked eye... Gross Matrix Healing Gross Matrix _ Healing Gross Burn Control e & a
Slide 35: Development of Nascent Hair Follicles
Development of Nascent Hair Follicles Hair shafts growing through a burn wound ina nude mouse after periwound m@ injection
Slide 36: Safety Data
Safety Data
Slide 37: What Comes After Skin Regeneration?
What Comes After Skin Regeneration? FDA Approved Competitor PolarityTE™ Bone Technology Regeneration Technology The PolarityTE™ platform has proved itself in bone, muscle, and nerve regeneration as well
Slide 38: The Holy Grail Of Tissue Regeneration: Blood Vessel Formation
The Holy Grail Of Tissue Regeneration: Blood Vessel Formation from Capillary bed formation within our bone regeneration construct sprouting surrounding native tissue AND FROM WITHIN our regenerative construct
Slide 39: A Platform Technology with Endless Possibilities
A Platform Technology with Endless Possibilities . . . @ sexx Ye ® \euralTE vice AdiposeTE
Slide 40: Strategy, Pathway, and Timelines
Strategy, Pathway, and Timelines Ski Te n Swine Data Human Pilot Trial in Burn Patients Product Registration and Market Entry Mi December 2017 > Manufacturing Optimization] December 2017 > Product Registration and Market Entry January 2018 March 2018 > Manufacturing Optimization
Slide 41: Sales & Financial Projections
les & Financial Projectio Financial Forecast 2017-2019 ie $30,000 8 g Ea 3 = ‘$25,000 $20,000 vw $300 $15,000 § & 5250 $10,000 $200 $5,000 $150 $100 i=] =] sad B — eso ee ee eee $50 eS ESBEESELT SEES SESLT ELSES SREP SESEESEE SEER EPSRC STIFF SSEPSS ESP TZESR IRS RFS ZFSEEB =| so ——- | ($5,000) _ —=
Slide 42: IP Opportunities
IP Opportunities ; oogle an : t : | | ute " i genzyMe bo! Epix 4 enn F Astrazeneca? z=
Slide 43: Manufacturing Capabilities
Manufacturing Capabilities (teal i Ee SCHOOL* MEDICINE Internal Medicine Fully Certified and J Highly Experienced cGTP/cGMP/CLIA Manufacturer Capable of Expanding as PolarityTE™ Grows
Slide 44: Predictable Scalability
Predictable Scalability he ali Self-Contained GMP Compliant 1 (315) 625-8025 Cell Processing and Production Facilities eww biospherixmedical.com move the incubator to the back and add a microscope chamber ‘add additional processing and incubation modules
Slide 45: Automated Manufacturing
Automated Manufacturing Automated Manufacturing is being Developed in Parallel to Increase Efficiency, while Decreasing Cost and Variability
Slide 46: The PolarityTEAM - Management
The PolarityTEAM - Management Denver M. Lough, MD, PhD Chairman, President, CEO, CSO = Inventor/innovator behind patented PolarityTE™ platform = MD/PhD from Georgetown University with Honors = Johns Hopkins Plastic and Reconstructive Surgery Training = Winner of numerous research awards, including b
Slide 47: The PolarityTEAM - Board of Directors
The PolarityTEAM — Board of Direc Denver Lough, MD, Pl ‘Chairman, Preside Chief Executi 3 q Michael Beeghley, ASA, MPH Jon Mogford, PAD) Director ; Director
Slide 48: The PolarityTEAM - Clinical Board of Advisors
The PolarityTEAM — Clinical Board of Advisors shannath Merbs, MO, PRO Prof ofOphitholmoloay and Oncology, Wilmer yest, Johns Hopkins Uni, ‘Anand Kumar, MD Ghigf of Plastic Surger Hospital Tiny sata 2. Chrstion Evenson ‘Oncology Depth ol Stephen Milner, MD, DDS/DSc, FRCSE, FACS Director of Clinical B
Slide 49: The PolarityTEAM
The PolarityTEAM Devin T. Miller, MD Director of Translational Research & Regulatory Strategy = MD from Johns Hopkins University = Over 5 years of translational science research experience in biological chemistry and transplant medicine = Prior Life Sciences Associate at Kairos Ventures evaluating p
Slide 50: Final Human Data Released
Final Human Data Released Human Proof of Concept Pilot Trial Initiated Product Prelim Human Swine Data Released Data Released Registration & Market Entry First Year in Market Sales of SkinTE™ Projected at $30M Conservatively Targeted Commercial Roll-Out at Limited Market Release (LMR) Burn/Wound Car
Slide 51: Capital Structure
Capital Structure Converted Options Common Stock Equivalents 7 a Polari tyIE Common Stock Diluted % Preferred Stock —— NAS DAQ: COOL Series A 792,933 4.60% PolarityTE.com Series B 801,820 4.65% Series C 410,247 2.38% Series D 157,776 0.92% Series E 7,050,000 40.91% Common Stock 4,976,768 28.88% ul S
Slide 52: Investment Summary
Investment Summary ale = a a —e - NN, eh An early stage preclinical regenerative medicine company with every attractive value inflection point still on the table: preclinical data, human proof of concept pilot trials, market entry, initial revenue generation, and commercial scale-up The proprietary
Slide 53: PolarityTE: Welcome to the Shift
Slide 54: Thank You
Thank You The PolarityTE™ TEAM PolarityTE™, Inc. NASDAQ: COOL www.PolarityTE.com [email protected]